<code id='A841F38485'></code><style id='A841F38485'></style>
    • <acronym id='A841F38485'></acronym>
      <center id='A841F38485'><center id='A841F38485'><tfoot id='A841F38485'></tfoot></center><abbr id='A841F38485'><dir id='A841F38485'><tfoot id='A841F38485'></tfoot><noframes id='A841F38485'>

    • <optgroup id='A841F38485'><strike id='A841F38485'><sup id='A841F38485'></sup></strike><code id='A841F38485'></code></optgroup>
        1. <b id='A841F38485'><label id='A841F38485'><select id='A841F38485'><dt id='A841F38485'><span id='A841F38485'></span></dt></select></label></b><u id='A841F38485'></u>
          <i id='A841F38485'><strike id='A841F38485'><tt id='A841F38485'><pre id='A841F38485'></pre></tt></strike></i>

          explore

          explore

          author:explore    Page View:173
          Novo Nordisk headquarters -- health coverage from STAT
          LISELOTTE SABROE/Scanpix/AFP via Getty Images

          LEXINGTON, Mass. — New obesity drugs like Wegovy and Zepbound are currently taken once a week, indefinitely. But what if they could be taken once a year instead, like a vaccine?

          That’s a question that Novo Nordisk, the pharma company behind Wegovy, is exploring as it faces increased competition from other drugmakers aiming to develop similar GLP-1-based treatments for obesity.

          advertisement

          “We have a very early think tank on: what would it take us, from a technology point of view and from an ecosystem point of view, to make long-lasting GLP-1 molecules?” Marcus Schindler, Novo’s chief scientific officer, said in an interview with STAT Wednesday. “Could we think about vaccine-like properties, where imagine you had, once a year, an injection with an equivalent of a GLP-1 that really helps you to maintain weight loss and have cardiovascular benefits?”

          Get unlimited access to award-winning journalism and exclusive events.

          Subscribe Log In

          comprehensive

          BioMarin wins approval for gene therapy to treat hemophilia A
          BioMarin wins approval for gene therapy to treat hemophilia A

          AdobeTheFoodandDrugAdministrationonThursdayapprovedagenetherapytotreatpeoplewithhemophiliaA,aninheri

          read more
          Doctors have an ethical obligation to be advocates
          Doctors have an ethical obligation to be advocates

          PhysicianCaitlinBernard,left,sitsbetweenattorneysJohnHooverandAliceMoricalonMay25,2023,beforeahearin

          read more
          The cancer drug shortage isn’t new — and neither are the solutions
          The cancer drug shortage isn’t new — and neither are the solutions

          PreparingachemotherapytreatmentatDukeCancerCenterinDurham,N.C.GerryBroome/APAyounggirl,maybe5or6year

          read more

          How to protect coverage of PrEP

          ApharmacistpoursTruvadapills,usedforPrEP,backintothebottleatapharmacyinSanAnselmo,Calif.JustinSulliv